Literature DB >> 12856386

Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects.

Shaker A Mousa1, Jeffrey Bozarth, Jeffrey S Barrett.   

Abstract

Low molecular weight heparins (LMWHs) stimulate the release of endothelial tissue factor pathway inhibitor (TFPI). An inhibitor of tissue factor-induced coagulation, TFPI may contribute to the efficacy of LMWHs. The release of TFPI may be affected by characteristics of LMWHs, such as molecular weight (MW) distribution. The authors measured plasma levels of TFPI after single, subcutaneous injections of tinzaparin (mean MW = 6500 Daltons [Da]; 3.5% of fractions < 2000 Da) or a tinzaparin-like LMWH (mean MW = 5650 Da; 18.3% of fractions < 2000 Da) in 30 healthy subjects. Maximum mean plasma levels of TFPI approached 200 to 230 ng/mL 0.8 hours after administration of either drug. Plasma levels of TFPI remained elevated compared with baseline values for 12 to 16 hours after drug administration. These results suggest that LMWH fractions < 2000 Da do not affect the release of TFPI.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12856386

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

Review 1.  Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis.

Authors:  Sheridan M Hoy; Lesley J Scott; Greg L Plosker
Journal:  Drugs       Date:  2010-07-09       Impact factor: 9.546

2.  Pharmacokinetics and pharmacodynamics of oral heparin solid dosage form in healthy human subjects.

Authors:  Shaker A Mousa; Fuming Zhang; Ahmad Aljada; Seema Chaturvedi; Majde Takieddin; Haifeng Zhang; Lianli Chi; M Cristina Castelli; Kristen Friedman; Michael M Goldberg; Robert J Linhardt
Journal:  J Clin Pharmacol       Date:  2007-12       Impact factor: 3.126

Review 3.  Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.

Authors:  Susan M Cheer; Christopher J Dunn; Rachel Foster
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 4.  Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease.

Authors:  Esther J van Zuuren; Zbys Fedorowicz
Journal:  Cochrane Database Syst Rev       Date:  2015-12-18

5.  Oral heparin: status review.

Authors:  Ehud Arbit; Michael Goldberg; Isabel Gomez-Orellana; Shingai Majuru
Journal:  Thromb J       Date:  2006-05-10

6.  Analysis of the protein-protein interaction networks of differentially expressed genes in pulmonary embolism.

Authors:  Hao Wang; Chen Wang; Lei Zhang; Yinghua Lu; Qianglin Duan; Zhu Gong; Aibin Liang; Haoming Song; Lemin Wang
Journal:  Mol Med Rep       Date:  2014-11-26       Impact factor: 2.952

Review 7.  "In Less than No Time": Feasibility of Rotational Thromboelastometry to Detect Anticoagulant Drugs Activity and to Guide Reversal Therapy.

Authors:  Vittorio Pavoni; Lara Gianesello; Duccio Conti; Piercarlo Ballo; Pietro Dattolo; Domenico Prisco; Klaus Görlinger
Journal:  J Clin Med       Date:  2022-03-04       Impact factor: 4.241

8.  Thromboelastometry versus free-oscillation rheometry and enoxaparin versus tinzaparin: an in-vitro study comparing two viscoelastic haemostatic tests' dose-responses to two low molecular weight heparins at the time of withdrawing epidural catheters from ten patients after major surgery.

Authors:  Owain Thomas; Anna Larsson; Nahreen Tynngård; Ulf Schött
Journal:  BMC Anesthesiol       Date:  2015-11-24       Impact factor: 2.217

Review 9.  Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented.

Authors:  Dominique Farge; Barbara Bournet; Thierry Conroy; Eric Vicaut; Janusz Rak; George Zogoulous; Jefferey Barkun; Mehdi Ouaissi; Louis Buscail; Corinne Frere
Journal:  Cancers (Basel)       Date:  2020-03-06       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.